- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Teva’s DuoResp Spiromax wins silver at the 2015 Medical Design Excellence Awards
2 July 2015 • Author: Victoria White
Teva’s DuoResp Spiromax inhaler has won silver at the 2015 Medical Design Excellence Awards (MDEA).
The awards recognise significant advances in medical product design that improve the quality of healthcare delivery. DuoResp Spiromax (budesonide/formoterol fumarate dihydrate) is a new multi-dose dry-powder inhaler for the management of asthma and chronic obstructive pulmonary disease (COPD).
“Innovative, patient-focused design is extremely important at a time when real-world behaviors and outcomes are what count,” said Rob Koremans, MD., President and CEO, Teva Global Specialty Medicines. “We are incredibly proud to be leading the way in providing people with asthma and COPD with inhalers that recognise and support their needs and long term health, and are delighted with this prestigious acknowledgment for DuoResp Spiromax.”
Spiromax inhaler provides consistent drug delivery across inspiratory flow rates
Many people with asthma and COPD are inadequately controlled as a consequence of poor inhaler technique which can lead to suboptimal outcomes in clinical practice and daily life.
DuoResp Spiromax represents a step forward in supporting improved inhaler technique and disease control. It contains a combination of budesonide, an inhaled corticosteroid to treat the underlying inflammation in asthma and COPD, and formoterol fumarate dihydrate, a long-acting beta2-adrenergic agonist for the relief of bronchoconstriction in asthma and COPD. With its design, the Spiromax inhaler incorporates a specific combination of features and provides consistent drug delivery across inspiratory flow rates. DuoResp Spiromax received marketing authorisation from the European Commission on the 29th of April 2014, and is currently available to patients in multiple countries across Europe.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics